Menopause

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

A new study presented at the 2024 Annual Meeting of the Menopause Society found cognitive behavioral therapy can effectively address sexual concerns during menopause, improving overall well-being.

Nanette Santoro, MD, and Lauren Streicher, MD, MSCP, briefly highlight why they feel the annual Menopause Society is a great place for learning and collaboration.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.

Female veterans with PTSD are twice as likely to experience early menopause and related health risks, according to a study presented at the 2024 Annual Meeting of The Menopause Society.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

A study presented at the 2024 Annual Meeting of The Menopause Society, found that women who reported physical intimate partner violence also demonstrated decreased working memory performance over time.

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

In a recent study, reduced aging discrepancies were observed in postmenopausal women reporting hormone therapy use vs nonusers.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Astellas Pharma has announced the first dose administration of fezolinetant to manage moderate to severe vasomotor symptoms in breast cancer patients using adjuvant endocrine therapy.

A significant connection has been identified between severe menopause symptoms and cognitive impairment in postmenopausal women, according to findings from a study published in Menopause, the journal of The Menopause Society.

A recent study found that women with a shorter reproductive lifespan had increased odds of multimorbidity compared to those with a longer reproductive lifespan, indicating a need to assess reproductive factors to determine high-risk patients.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Bayer has submitted a New Drug Application for elinzanetant, following positive results from the OASIS studies, showing significant safety and efficacy in treating moderate-to-severe vasomotor symptoms in menopausal women.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A new study recently published in Menopause, the journal of The Menopause Society, suggests a significant link between chronic kidney disease (CKD) and tooth loss, particularly in postmenopausal women.

Risa Kagan, MD, discusses the efficacy of fezolinetant in reducing the frequency and severity of vasomotor symptoms in menopausal women, offering an alternative to traditional hormonal therapies.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Though studies on the prevalence of depression during menopause vary, for those experiencing the symptoms, quality of life can be severely compromised.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research reveals that acute increases in physical activity and ambient temperature can elevate the risk of both objective and subjective hot flashes in postmenopausal women.

Review some of the top stories from Contemporary OB/GYN's coverage of ACOG 2024, and catch up on anything you may have missed.

Dive into the research presented by Rhonda R. Voskuhl at ACOG 2024, shedding light on the potential of estrogen receptor beta as a target to mitigate cognitive decline in postmenopausal women.

At ACOG 2024, Monica M. Christmas, MD, FACOG, and Stephanie Faubion, MD, emphasize the importance of combating disinformation in menopause care and provide clinicians with evidence-based strategies to manage symptoms effectively.

Phase 3 data presented by JoAnn Pinkerton, MD, reveals that elinzanetant significantly improves hot flash frequency, sleep, and overall menopause quality of life, offering a promising alternative to estrogen therapy.

Michelle Jacobson, MD, MHSc, FRCSC, shares critical perspectives on managing vasomotor symptoms in breast cancer patients at the recent ACOG Annual Clinical & Scientific Meeting, emphasizing the importance of tailored approaches amidst evolving treatment options and patient risks.